

**InRetail Pharma S.A. and Subsidiaries**

Interim consolidated financial statements as of December 31, 2021 (non-audited) and December 31, 2020 (audited) and for the twelve-month period ended December 31, 2021 and 2020

## **InRetail Pharma S.A. and Subsidiaries**

Interim consolidated financial statements as of December 31, 2021 and December 31, 2020 and for the twelve-month period ended December 31, 2021 and 2020.

## **Contents**

### **Interim consolidated financial statements**

Interim consolidated statements of financial position

Interim consolidated income statements

Interim consolidated statements of comprehensive income

Interim consolidated statements of changes in equity

Interim consolidated statements of cash flows

Notes to the interim consolidated financial statements

## InRetail Pharma S.A. and Subsidiaries

### Interim consolidated statements of financial position

As of December 31, 2021 (unaudited) and December 31, 2020 (audited)

	Note	2021 S/(000)	2020 S/(000)		Note	2021 S/(000)	2020 S/(000)
<b>Assets</b>				<b>Liabilities and equity</b>			
<b>Current assets</b>				<b>Current liabilities</b>			
Cash and short-term deposits	4	299,340	550,113	Trade payables	11	1,671,957	1,593,595
Trade receivables, net	5	510,014	523,091	Other payables		274,947	256,787
Other receivables, net		85,861	59,411	Accounts payable to related parties	19(b)	20,057	4,081
Accounts receivables from related parties	19(b)	10,341	7,935	Interest-bearing loans and borrowings	13	358,904	189,871
Inventories, net	6	1,367,590	1,186,698	Lease liability	12(c)	184,389	159,650
Taxes recoverable		189,563	99,022	Current income tax	14(b)	6,026	72,855
Prepayments		5,160	4,595	<b>Total current liabilities</b>		<b>2,516,280</b>	<b>2,276,839</b>
<b>Total current assets</b>		<b>2,467,869</b>	<b>2,430,865</b>				
<b>Non-current assets</b>				<b>Non-current liabilities</b>			
Other receivables, net		32,428	29,671	Other payables		2,231	1,653
Investments at fair value through equity	7	172,206	54,061	Accounts payable to related parties	19(b)	1,402,583	-
Derivative financial instrument	8	111,926	112,273	Interest-bearing loans and borrowings	13	990,239	2,033,994
Property, furniture and equipment, net	9	643,770	570,506	Lease liability	12(c)	383,822	448,648
Right-of-use assets, net	12(b)	510,596	572,850	Reserves for employee retirement pension funds		27,111	21,131
Intangible assets, net	10	1,853,939	1,940,470	Deferred income tax liabilities, net	14(a)	167,087	206,516
Deferred income tax assets, net	14(a)	112,340	84,887	<b>Total non-current liabilities</b>		<b>2,973,073</b>	<b>2,711,942</b>
Other assets		2,463	7,949	<b>Total liabilities</b>		<b>5,489,353</b>	<b>4,988,781</b>
<b>Total non-current assets</b>		<b>3,439,668</b>	<b>3,372,667</b>	<b>Equity</b>			
<b>Total assets</b>		<b>5,907,537</b>	<b>5,803,532</b>	Capital stock	15(a)	15,840	15,840
				Capital premium	15(b)	482,835	482,835
				Other reserves		32,883	21,023
				Unrealized results from derivative financial instruments		(54,514)	(46,668)
				Unrealized results from valuation of investment at fair value		13,265	14,774
				Unrealized results from actuarial reserve for retirement		739	1,065
				Unrealized results from foreign currency translation		4,094	2,115
				Retained earnings		(76,958)	323,767
				<b>Total equity</b>		<b>418,184</b>	<b>814,751</b>
				<b>Total liabilities and equity</b>		<b>5,907,537</b>	<b>5,803,532</b>

The accompanying notes are an integral part of these consolidated statements.

## InRetail Pharma S.A. and Subsidiaries

### Interim consolidated Income statements

For the twelve-month period ended December 31, 2021 and 2020

	Note	2021 S/(000)	2020 S/(000)
Net sales of goods		7,740,955	6,908,176
Rental income		103,400	92,876
Rendering of services		220,133	190,431
<b>Revenue</b>		<b>8,064,488</b>	<b>7,191,483</b>
Cost of sales	17	(5,578,665)	(4,992,245)
<b>Gross profit</b>		<b>2,485,823</b>	<b>2,199,238</b>
Selling expenses	17	(1,494,405)	(1,271,772)
Administrative expenses	17	(301,698)	(287,583)
Other operating income, net		7,614	9,483
<b>Operating profit</b>		<b>697,334</b>	<b>649,366</b>
Financial income		8,509	9,631
Financial expenses	18	(318,140)	(190,469)
Exchange difference, net		(28,960)	(44,509)
<b>Profit before income tax</b>		<b>358,743</b>	<b>424,019</b>
Income tax expense	14(a)	(137,399)	(141,458)
<b>Net profit</b>		<b>221,344</b>	<b>282,561</b>
<b>Earnings per share:</b>			
Basic and diluted profit for the period	20	13.974	17.839

All items above are related to continuing operations.

The accompanying notes are an integral part of these consolidated statements.

## InRetail Pharma S.A. and Subsidiaries

Interim consolidated statements of comprehensive income  
For the twelve-month period ended December 31, 2021 and 2020

	<b>2021</b>	<b>2020</b>
	S/(000)	S/(000)
<b>Profit for the period</b>	221,344	282,561
<b>Other comprehensive income</b>		
Unrealized (loss) gain on investments at fair value through equity	(2,140)	8,627
Income tax effect	631	(2,545)
<b>Total other comprehensive income from investments at fair value through equity</b>	<b>(1,509)</b>	<b>6,082</b>
Unrealized loss from derivative financial instrument	(11,129)	(61,412)
Income tax effect	3,283	18,117
<b>Total comprehensive income from derivative financial instruments</b>	<b>(7,846)</b>	<b>(43,295)</b>
Unrealized (loss) gain from actuarial reserve for retirement	(326)	588
<b>Total comprehensive income from actuarial reserve for retirement</b>	<b>(326)</b>	<b>588</b>
Unrealized gain from foreign currency translation	1,809	1,674
<b>Total comprehensive income from foreign currency translation</b>	<b>1,809</b>	<b>1,674</b>
<b>Other comprehensive income for the period, net of income tax effects</b>	<b>(7,872)</b>	<b>(34,951)</b>
<b>Total comprehensive income for the period</b>	<b>213,472</b>	<b>247,610</b>

The accompanying notes are an integral part of these consolidated statements.

## InRetail Pharma S.A. and Subsidiaries

### Interim consolidated statements of change in equity

For the twelve-month period ended December 31, 2021 and 2020

	Capital stock	Capital premium	Other reserves	Unrealized results from derivative financial instrument	Unrealized results from investment at fair value through equity	Unrealized results from actuarial reserve for retirement	Unrealized results from foreign currency translation	Retained earnings	Total equity
	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)
<b>Balance as of January 1, 2020</b>	<b>15,840</b>	<b>482,835</b>	<b>2,449</b>	<b>(3,373)</b>	<b>8,692</b>	<b>477</b>	<b>(239)</b>	<b>269,819</b>	<b>776,500</b>
Profit for the period	-	-	-	-	-	-	-	282,561	282,561
Other comprehensive income	-	-	-	(43,295)	6,082	588	1,674	-	(34,951)
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(43,295)</b>	<b>6,082</b>	<b>588</b>	<b>1,674</b>	<b>282,561</b>	<b>247,610</b>
Dividends paid	-	-	-	-	-	-	-	(209,362)	(209,362)
Transfer to other reserve	-	-	18,589	-	-	-	-	(18,589)	-
Other	-	-	(15)	-	-	-	680	(662)	3
<b>Balance as of December 31, 2020</b>	<b>15,840</b>	<b>482,835</b>	<b>21,023</b>	<b>(46,668)</b>	<b>14,774</b>	<b>1,065</b>	<b>2,115</b>	<b>323,767</b>	<b>814,751</b>
<b>Balance as of January 1, 2021</b>	<b>15,840</b>	<b>482,835</b>	<b>21,023</b>	<b>(46,668)</b>	<b>14,774</b>	<b>1,065</b>	<b>2,115</b>	<b>323,767</b>	<b>814,751</b>
Profit for the period	-	-	-	-	-	-	-	221,344	221,344
Other comprehensive income	-	-	-	(7,846)	(1,509)	(326)	1,809	-	(7,872)
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(7,846)</b>	<b>(1,509)</b>	<b>(326)</b>	<b>1,809</b>	<b>221,344</b>	<b>213,472</b>
Dividends paid	-	-	-	-	-	-	-	(610,039)	(610,039)
Transfer to other reserve	-	-	15,885	-	-	-	-	(15,885)	-
Other equity change	-	-	(4,025)	-	-	-	170	3,855	-
<b>Balance as of December 31, 2021</b>	<b>15,840</b>	<b>482,835</b>	<b>32,883</b>	<b>(54,514)</b>	<b>13,265</b>	<b>739</b>	<b>4,094</b>	<b>(76,958)</b>	<b>418,184</b>

The accompanying notes are an integral part of these consolidated statements.

## InRetail Pharma S.A. and Subsidiaries

### Interim consolidated statements of cash flows

For the twelve-month period ended December 31, 2021 and 2020

	Note	2021 S/(000)	2020 S/(000)
<b>Operating activities</b>			
Revenue		8,039,114	7,143,669
Payment of goods and services to suppliers		(6,240,551)	(5,487,417)
Payment of salaries and social benefits to employees		(841,221)	(786,807)
Taxes paid		(310,332)	(193,236)
Recovery of taxes		1,713	3,938
Other payments, net		(2,652)	(12,776)
<b>Net cash flows from operating activities</b>		<b>646,071</b>	<b>667,371</b>
<b>Investing activities</b>			
Collection of loans granted to related parties		-	111,000
Purchase of investments at fair value through equity	7	(124,345)	-
Sale of subsidiary, net of cash delivered		37,372	5,834
Purchase of property, furniture and equipment, net of acquisitions through leasing contracts		(126,437)	(73,176)
Loans granted to related parties		-	(111,000)
Purchase and development of intangible assets		(43,024)	(23,206)
<b>Net cash flows used in investing activities</b>		<b>(256,434)</b>	<b>(90,548)</b>
<b>Financing activities</b>			
Proceeds from interest-bearing loans and borrowings, net of structuring cost		937,548	656,143
Proceeds from related entity loans		1,336,320	-
Proceeds from derivative financial instrument settlement		21,385	-
Payment of issued bonds		(1,478,000)	-
Payment of premium for advanced cancelation of senior notes		(47,530)	-
Payment of interest-bearing loans and borrowings		(433,222)	(674,579)
Payment of lease liability	12	(242,074)	(216,407)
Interest payment of lease liability	12	(43,347)	(44,137)
Payment of dividends		(610,039)	(209,362)
Interest paid		(81,451)	(127,621)
<b>Net cash flows used in financing activities</b>		<b>(640,410)</b>	<b>(615,963)</b>
Net decrease of cash and short-term deposits		(250,773)	(39,140)
<b>Cash and short-term deposits at the beginning of the period</b>		<b>550,113</b>	<b>589,253</b>
<b>Cash and short-term deposits at the end of the period</b>		<b>299,340</b>	<b>550,113</b>
<b>Non-cash transactions</b>			
Fixed assets purchased through leasing and other financial obligations		40,602	5,270
Addition of right-of-use assets		190,031	118,334

The accompanying notes are an integral part of these consolidated statements

## Notes to the interim consolidated financial statements (continued)

### InRetail Pharma S.A. and Subsidiaries

#### Notes to the interim condensed consolidated financial statements

As of December 31, 2021 and December 31, 2020 and for the twelve-month period ended December 31, 2021 and 2020

#### 1. Identification, business activity, reorganization process, disposal subsidiaries and pandemic

##### (a) Identification

InRetail Pharma S.A. (hereinafter “the Company”), was incorporated on August 2, 1996. As of December 31, 2021 and December 31, 2020, the Company is a subsidiary of InRetail Perú Corp. which holds 87.02 percent of the Company’s capital stock. Likewise, InRetail Perú Corp. is a subsidiary of Intercorp Retail Inc., which is one of the entities of the Intercorp Perú Group operating in Peru and abroad.

The Company’s legal address, where its administrative offices operate, is Av. Defensores del Morro N ° 1277, Chorrillos, Lima, Republic of Peru.

##### (b) Business activity

The Company and its Subsidiaries Drogueria InRetail Pharma S.A.C., Farmacias Peruanas S.A.C., Mifarma S.A.C., Química Suiza S.A.C., Boticas IP S.A.C., Jorsa de la Selva S.A.C., Vanttive S.A.C., FP Servicios Generales S.A.C. and Quicorp S.A. and Subsidiaries (hereinafter and together “InRetail Pharma Group”) are mainly dedicated to operating pharmacies and to the distribution of pharmaceutical products. The InRetail Pharma Group operations are concentrated in the Andean region, with its core market in Peru.

##### (c) Reorganization process

In order to present a more efficient and organized structure, during 2021 and 2020, several corporate reorganization processes were performed, which involve some subsidiaries as Droguería InRetail Pharma S.A.C., Farmacias Peruanas S.A.C., Mifarma S.A.C., Albis S.A.C., Cifarma S.A.C., Boticas del Oriente S.A.C., Eckerd Amazonia S.A.C. and Quicorp S.A.; however, considering that said subsidiaries were controlled, directly and indirectly, by the Company and/or its shareholders since previous years, such reorganization processes had no impact on the consolidated financial statements as of December 31, 2021 and December 31, 2020.

##### (d) Disposal of subsidiaries

On January 22 and February 26, 2021, InRetail Pharma Group transferred 100 percent of its participation in Química Suiza Colombia S.A.S. and Cifarma S.A.C. for approximately US\$1,958,000 (equivalent to S/7,093,000) and US\$9,545,000 (equivalent to S/34,879,000), to non-related entities.

On October 5, 2020, InRetail Pharma Group sold the shareholder interest in their Bolivian subsidiary Mifarma S.A. for approximately US\$2,000,000 (equivalent to S/7,233,000), to a non-related entity.



## Notes to the interim consolidated financial statements (continued)

The following are the assets and liabilities, at the date of disposals:

	2021		2020
	Quimica Suiza Colombia S.A.S. S/(000)	Cifarma S.A.C. (Peru) S/(000)	Mifarma S.A. (Bolivia) S/(000)
<b>Assets</b>			
Cash and short-term deposits	2,085	2,514	1,399
Inventories	4,487	20,001	8,522
Property, furniture and equipment, net	207	10,617	809
Right-of-use assets, net	57	16,960	891
Intangible assets, net	-	6,907	-
Other	9,533	25,475	610
	<b>16,369</b>	<b>82,474</b>	<b>12,231</b>
<b>Liabilities</b>			
Trade accounts payables	6,709	14,018	7,586
Lease liabilities	92	20,164	890
Other	5,154	6,641	2,327
	<b>11,955</b>	<b>40,823</b>	<b>10,803</b>
<b>Net value</b>	<b>4,414</b>	<b>41,651</b>	<b>1,428</b>

### e) Pandemic

In March 2020, the World Health Agency "WHO" declared the coronavirus outbreak as a pandemic. The Company and its Subsidiaries have taken all the appropriate measures to safeguard the health of workers and ensure their critical processes.

On January 26, 2021, the government of Peru announced new quarantine measures for the country to contain the virus, applying different measures in each region according to four different alert levels: extreme, very high, high and moderate. Measures were initially applicable for 15 days, from January 31, 2021 to February 15, 2021, but were extended to February 28, 2021.

On February 24, 2021, the government of Peru announced the lifting of the quarantine measures in the country from March 1, 2021 to March 14, 2021. During this period, all shopping centers were allowed to operate both essential and non-essential retail, but with restrictions on maximum visitor capacity between 20 and 60 percent which varied depending on the tenant and risk level in each region.

On April 14, 2021, the government of Peru announced that, due to an increase in infections, several regions of the country would return to the level of extreme risk, where the allowed capacity in shopping centers was 20 percent that mandate would last from April 19 to May 5, 2021.

Since July 12, 2021, restrictions on Sundays were lifted, capacity in Shopping Malls was increased to 50 percent, and opening hours were increased until 10 pm. Since September 6, 2021, most regions have been classified in the lowest risk level.

The Peruvian Government announced that, due to the increase in infections, several regions of the country would return to the high risk level, where the capacity allowed in shopping centers will be 60 percent, which will be in force from December 15, 2021 to January 30, 2022.

These restrictions did not affect essential activities such as the supply of pharmaceutical products.

## Notes to the interim consolidated financial statements (continued)

The Company's Management and its subsidiaries estimate that the pandemic will not have a significant impact on the consolidated financial statements.

The accompanying interim consolidated financial statements as of December 31, 2021 and 2020 were approved by the Board of Directors on February 28, 2022.

### 2. Subsidiary activities

The Company and its Subsidiaries (hereinafter the "InRetail Pharma Group") are dedicated to the commercialization, manufacturing, distribution and marketing, nationally and internationally, of pharmaceutical products, cosmetics, food for medical use and other foods intended for protection and recovery of health through its "Inkafarma" and "Mifarma" pharmacy chains. The company and its subsidiaries operate 2,249 stores as of December 31, 2021 (2,165 stores as of December 31, 2020) and have operations in Peru, Ecuador and Bolivia as of December 31, 2021 (Peru, Colombia, Ecuador and Bolivia as of December 31, 2020).

The description of the activities of the main Subsidiaries of the Company is as follows:

- (a) Droguería InRetail Pharma S.A.C. began operations in August 2020. Its economic activity is the purchase and wholesale of pharmaceutical products, personal care and other products for the protection and recovery of health.
- (b) Farmacias Peruanas S.A.C. started operations in August 2020. Its economic activity is to provide business, administrative and logistical services for the companies of the Pharma group.
- (c) Eckerd Amazonia S.A.C. was incorporated and started its activities in September 2001. It is dedicated to the commercialization of pharmaceutical products, cosmetic products, food for medical use and other elements aimed for health protection and recovery through its "Inkafarma" pharmacy chain. This Subsidiary's legal address is Alfonso Ugarte Avenue 1283, Loreto, Iquitos, Peru.

At the General Shareholders' Meeting of September 1, 2021, the merger of the Company with Jorsa de la Selva S.A.C. was agreed, in which the latter would act as the absorbing company, therefore, Eckerd Amazonia S.A.C. extinguished without the need to be dissolved or liquidated.

- (d) Boticas del Oriente S.A.C. was incorporated and started its activities in December 2007. It is dedicated to the commercialization of pharmaceutical products, cosmetic products, food for medical use and other elements aimed for health protection and recovery through its "Inkafarma" pharmacy chain. This Subsidiary's legal address is Alfonso Ugarte Avenue 1283, Loreto, Iquitos, Peru.

At the General Shareholders' Meeting of September 1, 2021, the merger of the Company with Jorsa de la Selva S.A.C. was agreed, in which the latter would act as the absorbing company, therefore, Boticas del Orientes S.A.C. extinguished without the need to be dissolved or liquidated.

- (e) Mifarma S.A.C.

It is a subsidiary of InRetail Pharma S.A., product of the spin-off approved on September 1, 2021, which owns 99.99 percent of its capital. It was incorporated on November 22, 2005. Until August 31, 2021, it was a subsidiary of Quicorp S.A. Previously, it was a subsidiary of Química Suiza S.A.C. until April 30, 2019. The legal address of the subsidiary is Calle Víctor Alzamora N ° 147, Urb. Santa Catalina, Lima, Peru.

## Notes to the interim consolidated financial statements (continued)

It is dedicated to retail of pharmaceutical products, cosmetics, perfumery, hygiene, hygiene and personal care and other products for the protection and recovery of health.

The company maintains 99.99 percent of the equity of the following companies:

i. Albis S.A.C.

It is a legal entity established in 1998 as a result of the merger of Distribuidora Albis S.A. with Albis Data S.A. It is a subsidiary of Mifarma S.A.C., which owns 99.99 percent of its capital.

It is dedicated to the commercialization of pharmaceutical, cosmetic, perfumery, health, hygiene and personal care products and other products for the protection and recovery of health throughout the country.

At the General Shareholders' Meeting, on August 1, 2019, of Albis S.A.C. and Cifarma S.A.C. the reorganization of both companies was approved, through this reorganization, Albis S.A.C. segregates and transfers an equity block to Cifarma S.A.C. composed of assets and liabilities related to the laboratory business. The net value of the equity block is S/9,555,163, which was contributed to Cifarma S.A.C.

At the General Shareholders' Meeting of October 1, 2021, was approved, the merger of Albis S.A.C. with Mifarma S.A.C. in which the latter acts as absorbent, therefore, Albis S.A.C. is extinguished without the need to be dissolved or liquidated.

ii. Jorsa de la Selva S.A.C.

It is a legal entity, a subsidiary of Albis S.A.C., dedicated mainly to the commercialization of pharmaceutical products, cosmetics, perfumery, hygiene, personal care and other products for the protection and recovery of health. The Company's legal address is located at Av. Elías Aguirre 1107, Loreto, Peru.

At the General Shareholders' Meeting on September 1, 2021, the merger of the Jorsa de la Selva S.A.C. with Eckerd Amazonia S.A.C. and Boticas del Oriente S.A.C., was approved in which Jorsa de la Selva S.A.C. would act as the absorbing company, therefore, Eckerd Amazonia S.A.C. and Boticas del Oriente S.A.C. extinguished without the need to be dissolved or liquidated.

(f) Química Suiza S.A.C.

Incorporated in Peru on March 6, 1939 and its legal address is located at Av. República de Panamá N°2577, Lima, Peru. It is a subsidiary of InRetail Pharma S.A., as result of the spin-off approved by the General Shareholders' Meeting on September 1, 2021, who owns 99.99 percent of its capital.

It is dedicated to the import, representation and commercialization of pharmaceutical, food, cosmetic, chemical, liquor and consumer products in general. Additionally, it obtains commissions for the intermediation in the sale of raw materials on behalf of foreign suppliers.

The company holds 99.99 percent of the equity of Vanttive S.A.C.

i. Vanttive S.A.C.

It was incorporated in Peru on July 11, 2012. It is a direct subsidiary of Química Suiza S.A.C., a company incorporated in Peru, which owns 99.99 percent of its capital stock as of December 31, 2021 and December 31, 2020. Its Legal address is located in Av. República de Panamá N ° 2577, La Victoria, Lima.

## Notes to the interim consolidated financial statements (continued)

It is engaged in the wholesaling and retailing, warehousing, distribution, over the counter and manufacturing of natural and pharmaceutical health products, specifically for patients undergoing cancer treatment.

In addition, it can engage in the provision of services as a medical center in the category of doctor's office for the purpose of prevention, promotion, diagnosis, medical treatment and rehabilitation in order to keep people in a healthy state.

- (g) Quicorp S.A. is a Holding incorporated in Peru in September 2010. At the General Shareholders' Meeting on September 1, 2021, the division of an equity block in favor of InRetail Pharma S.A. of the shares of Quimica Suiza S.A.C. and Mifarma S.A.C. was approved.

The Company maintains 99.99 percent of the equity of the following Companies:

- i. Quifatex S.A. S.A.C.

It was incorporated on May 26, 1978 in the city of Quito, Ecuador. The registered office is located at Av. 10 de Agosto 10640 y Manuel Zambrano, Quito, Ecuador. It is controlled and supervised by the Superintendence of Corporations in the Republic of Ecuador.

It is dedicated to the commercialization, distribution, representation, import, and export of pharmaceutical, nutrition, chemical, cosmetic, food, veterinary, insecticidal, fertilizing products and liquors and well as tools and machinery in general.

The company maintains 99.99 percent of the equity of Vanttive Cía. Ltda.

- Vanttive Cía. Ltda.

It was incorporated on July 17, 2003 in the city of Quito, Ecuador. The registered office is located at Av. 10 de Agosto 10640 y Manuel Zambrano, Quito, Ecuador. It is controlled and supervised by the Superintendence of Corporations in the Republic of Ecuador.

It is dedicated to the import, export, commercialization, distribution, and intermediation of specialized pharmaceutical products.

- ii. Quimiza Ltda.

It was incorporated on August 26, 1978. It is a distributor in the cities of Tarija, Oruro, and Potosí, as well as a distribution center in Santa Cruz, Bolivia. In addition, it has offices, agencies, and branches in other districts of the country. Currently, it has four offices in the cities of Santa Cruz (main office), La Paz, Cochabamba, and Sucre.

It is dedicated to the manufacture, commercialization, distribution, import, export, and representation of chemical, pharmaceutical, dietary, veterinary, cosmetic, insecticidal and fertilizing products, as well as machinery and equipment for the industry and consumables in general. Currently, it imports and commercializes pharmaceutical, industrial, consumption and veterinary products, expanding its market by signing new representation agreements.

- iii. Cifarma S.A.C.

It was incorporated in Peru on July 1, 1992. It is a Subsidiary of Quicorp S.A., product of the spin-off approved on May 1, 2019, who owns 99.99 percent of its share capital. Until April 30, 2019, it was a subsidiary of Quimica Suiza S.A.C. and up to September 30, 2010, Cifarma S.A.C. was a Subsidiary of Roxilan S.A., a company incorporated in Switzerland, which owned 71.96 percent of its capital. The registered office of Cifarma S.A. is located at Carretera Central Km. 3 N° 1315 Santa Anita, Lima, Perú.

## Notes to the interim consolidated financial statements (continued)

Cifarma S.A.C. provides services related to manufacturing and packaging of pharmaceutical, cosmetic and chemical products, with Química Suiza S.A.C. as its main client.

In February 2021, Cifarma S.A.C., was sold to an unrelated third party, the amount of the sale was S/34,879,000. See Note 1 (d).

iv. Mifarma S.A.

It was incorporated in La Paz, Bolivia on March 12, 2010. It is dedicated to the import, export, purchase, sale, production, by itself or third parties, and trade of all pharmaceutical and medical products in general belonging to local and foreign companies it represents.

In October 2020, Mifarma Bolivia, which operated 23 pharmacies, was sold to an unrelated third party, the amount of the sale was S/7,233,000. See Note 1 (d).

v. Quimica Suiza Colombia S.A.S. (Formerly Quideca S.A.)

It was incorporated on March 13, 2006 in Bogota, Colombia and is legally effective up to March 13, 2056.

It is dedicated to the purchase, sale, commercialization, promotion, distribution, representation, import, and export of health and pharmaceutical products, including vaccines, food, cosmetic, hygiene, personal care and home products. It also trades pesticides, herbicides, insecticides, fertilizers, chemical and agrochemical products, construction additives, tools, and equipment.

In January 2021, Quimica Suiza Colombia S.A.S., was sold to an unrelated third party, the amount of the sale was S/7,093,000. See Note 1 (d).

### 3. Basis of preparation and presentation, changes in the accounting policies of the Pharma group

(a) Interim financial statements

The consolidated financial statements of the InRetail Pharma Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Boards (IASB), effective as of December 31, 2021 and December 31, 2020, respectively.

The interim financial statements of the InRetail Pharma Group have been prepared in accordance with IAS 34 "Interim Financial Reporting".

The interim financial information does not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the audited annual information.

The consolidated financial statements have been prepared on a historical cost basis, except for financial instruments at fair value through profit and loss, financial instruments at fair value through other comprehensive income and derivative financial instruments. The consolidated financial statements are presented in Soles and all values are rounded to the nearest thousand (S/(000)), except when otherwise indicated.

The functional currency of the subsidiaries domiciled in Ecuador, Bolivia and Colombia are the local currency in those countries. These currencies do not belong to hyperinflationary economies. All transactions are measured in the functional currency.

## Notes to the interim consolidated financial statements (continued)

The result and the financial position of all the Group companies (none of which has the currency for a hyperinflationary economy), that have a functional currency other than the InRetail Pharma S.A.'s presentation currency are translated into the presentation currency as follows:

- Assets and liabilities for each statement of financial position presented (including comparatives) shall be translated at the closing exchange rate at the date of the statement of financial position;
- Income and expenses for each statement presenting profit or loss and other comprehensive income (including comparatives) shall be translated at the average exchange rates for the corresponding year;
- Equity accounts shall be translated at the exchange rates at the date of the transactions; and
- All resulting exchange differences shall be recognized in other comprehensive income as profit or loss on translation.

At the date of this report, all the entities consolidated into the accompanying financial statements are legal subsidiaries of InRetail Pharma S.A.

### (b) Basis of consolidation

The consolidated financial statements comprise the financial statements of the Company and its subsidiaries, see Note 2.

Subsidiaries are fully consolidated from the date of acquisition, being the date on which the InRetail Pharma Group obtains control, and continues to be consolidated until the date when such control ceases. The financial statements of the subsidiaries are prepared for the same period as the parent company, using consistent accounting policies. All intra-group balances, transactions, unrealized gains and losses resulting from intra-group transactions and dividends are eliminated in full.

The non-controlling interests have been determined in proportion to the participation of minority shareholders in the net equity and the results of the subsidiaries in which they hold shares, and they are presented separately in the consolidated statement of financial position and the consolidated statement of comprehensive income.

Losses in a subsidiary are attributed to the non-controlling interest even if that results in a deficit balance. A change in the ownership interest of the subsidiary, without a loss of control, is accounted as an equity transaction.

The accounting policies followed in the preparation of the consolidated financial statements are consistent with those followed in the preparation of the consolidated financial statements as of December 31, 2020.

### (c) New accounting standards

The accounting policies adopted in the preparation of the interim combined financial statements are consistent with those followed in the preparation of the Companies annual combined financial statements for the year ended December 31, 2020, except for the adoption of the new standards and interpretations as of January 1, 2020.

## Notes to the interim consolidated financial statements (continued)

The standards and amendments, and improvements to the standards that are issued, and effective up to the date of issuance of the accompanying consolidated financial statements, are disclosed below:

(i) Amendments to IFRS 3 “Business combinations”: Reference to the Conceptual Framework

In May 2020, the IASB issued Amendments to IFRS 3, intended to replace a reference to the Framework for the Preparation and Presentation of Financial Statements, issued in 1989 with a reference to the Conceptual Framework for Financial Reporting issued in March 2018 without significantly changing its requirements. The Board also added an exception to the recognition principle of IFRS 3 to avoid the issue of potential ‘Day 2’ gain or losses arising for liabilities and contingent liabilities that would be within the scope of IAS 37 or IFRIC 21 “Levies”, if uncured separately.

At the same time, the Board decided to clarify existing guidance in IFRS 3 for contingent assets that would not be affected by replacing the reference to the Framework for the Preparation and Presentation of Financial Statements. The amendments are effective for annual reporting periods beginning on or after January 1, 2022 and apply prospectively.

Since the amendments apply prospectively to transactions or other events that occur on or after the date of the first application, the InRetail Group will not be affected by these amendments on transition.

(ii) Modifications to IAS 1 “Presentation of financial statements” Classification of Liabilities as Current or Non-current

In January 2020, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The amendments clarify: (i) what is meant by a right to defer settlement; (ii) that a right to defer must exist at the end of the reporting period; (iii) that classification is unaffected by the likelihood that an entity will exercise its deferral right; and, (iv) that only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification. The amendments are effective for annual reporting periods beginning on or after January 1, 2023 and must be applied retrospectively.

The InRetail Pharma Group is currently assessing the impact the amendments will have on current practice and whether existing loan agreements may require renegotiation.

(iii) Amendments to IAS 16 “Property, plant and equipment”: Proceeds before intended Use

In May 2020, the IASB issued amendments to IAS 16, which prohibits entities deducting from the cost of an item of property, plant and equipment, any proceeds from selling items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognizes the proceeds from selling such items, and the costs of producing those items, in profit or loss. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 and must be applied retrospectively to items of property, plant and equipment made available for use on or after the beginning of the earliest period presented when the entity first applies the amendment.

The amendments are not expected to have a material impact on the InRetail Pharma Group.

## Notes to the interim consolidated financial statements (continued)

- (iv) Amendments to IAS 37 “Provisions, contingent liabilities and contingent assets”: Onerous Contracts – Costs of Fulfilling a Contract

In May 2020, the IASB issued amendments to IAS 37 to specify which costs an entity needs to include when assessing whether a contract is onerous or loss-making. The amendments apply a “directly related cost approach”. The costs that relate directly to a contract to provide goods or services include both incremental costs and an allocation of costs directly related to contract activities. General and administrative costs do not relate directly to a contract and are excluded unless they are explicitly chargeable to the counterparty under the contract. The amendments are effective for annual reporting periods beginning on or after January 1, 2022.

The InRetail Group will apply these amendments to contracts for which it has not yet fulfilled all its obligations at the beginning of the annual reporting period in which it first applies the amendments.

- (v) Annual Improvements (2018-2020 cycle)

As part of its 2018-2020 annual improvement to IFRS standards process, the IASB issued the following amendments:

- IFRS 1 “First-time adoption of international financial reporting standards”: Subsidiary as a first-time adopter

The amendment permits a subsidiary that elects to apply paragraph D16(a) of IFRS1 to measure cumulative translation differences using the amounts reported by the parent, based on the parent’s date of transition to IFRS. This amendment is also applied to an associate or joint venture that elects to apply paragraph D16(a) of IFRS 1. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 with earlier adoption permitted.

- IFRS 9 “Financial instruments”: Fees in the ‘10 percent’ test for derecognition of financial liabilities

The amendment clarifies the fees that an entity includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. These fees include only those paid or received between the borrower and the lender, including fees paid or received by either the borrower or lender on the other’s behalf. An entity applies the amendment to financial liabilities that are modified or exchanged on or after the beginning of the annual reporting period in which the entity first applies the amendment. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 with earlier adoption permitted.

- IAS 41 “Agriculture”: Taxation in fair value measurements

The amendment removes the requirement in paragraph 22 of IAS 41 that entities exclude cash flows for taxation when measuring the fair value of assets within the scope of IAS 41. An entity applies the amendment prospectively to fair value measurements on or after the beginning of the first annual reporting period beginning on or after January 1, 2022 with earlier adoption permitted.

In the Management's opinion, these standards will not have a significant impact on the consolidated financial statements of the InRetail Pharma Group.



## Notes to the interim consolidated financial statements (continued)

### 4. Cash and short-term deposits

(a) The table below presents the components of this account:

	As of December 31, 2021 S/(000)	As of December 31, 2020 S/(000)
Cash (b)	5,896	6,186
Current accounts (c)	242,126	507,495
Other deposits (d)	4	639
Cash in transit	51,314	35,793
<b>Total</b>	<b>299,340</b>	<b>550,113</b>

(b) Comprises mainly cash held by subsidiaries in the premises of their store chains and in the vaults of a security company, corresponding to sales during the last days of the period.

(c) The company and its Subsidiaries maintain current accounts in local banks in the currency of each country and US Dollars. They do not accrue interest and are freely available.

(d) As of December 31, 2021, corresponds to a savings account balance in U.S. dollars of a foreign subsidiary (as of December 31, 2020, corresponds to term deposits between 1.50 and 1.62 percent annually in Colombian Pesos).

### 5. Trade receivables, net

(a) The table below presents the components of this item:

	As of December 31, 2021 S/(000)	As of December 31, 2020 S/(000)
Trade accounts receivable (b)	530,162	558,690
Credit card operators (c)	18,110	13,145
<b>Total</b>	<b>548,272</b>	<b>571,835</b>
Provision for doubtful accounts (d)	(38,258)	(48,744)
<b>Total</b>	<b>510,014</b>	<b>523,091</b>

(b) Trade receivables are denominated in the currency of each country and US Dollars, have current maturity and do not bear interest.

(c) Corresponds mainly to pending deposits in favor of InRetail Pharma Group for the last days of the month, held by credit card operators and originated from the sale of goods with credit cards in the different stores of InRetail Pharma Group.

## Notes to the interim consolidated financial statements (continued)

- (d) The movement in the provision for doubtful accounts receivables for the twelve-month period ended December 31, 2021 and 2020, were as follows:

	<b>2021</b> S/(000)	<b>2020</b> S/(000)
<b>Balance at the beginning of the period</b>	<b>48,744</b>	<b>44,734</b>
Provision recognized as expense, Note 17 (a)	8,264	8,827
Recoveries, Note 17 (a)	(2,496)	(1,514)
Write-offs	(18,433)	(5,000)
Foreign currency translation	2,179	1,697
<b>Balance at the end of the period</b>	<b>38,258</b>	<b>48,744</b>

As of December 31, 2021 and December 31, 2020, the amount of overdue account receivables but non-impaired amounted to approximately S/77,423,000 and S/86,504,000, respectively.

In the opinion of Management of the InRetail Pharma Group, the provision for doubtful accounts receivables as of December 31, 2021 and December 31, 2020, appropriately covers the credit risk of this item at those dates.

### 6. Inventories, net

- (a) The composition of this item is presented below:

	<b>As of December 31, 2021</b> S/(000)	<b>As of December 31, 2020</b> S/(000)
Goods, Note 17 (a)	1,235,924	1,091,368
In transit inventories (b)	137,741	87,023
Raw material, Note 17 (a)	860	19,552
Miscellaneous supplies	6,968	3,393
Miscellaneous supplies for manufacturing, Note 17 (a)	874	550
Finished goods, Note 17 (a)	-	455
<b>Total</b>	<b>1,382,367</b>	<b>1,202,341</b>
<b>Minus</b>		
Provision for impairment of inventories (c)	(14,777)	(15,643)
<b>Total</b>	<b>1,367,590</b>	<b>1,186,698</b>

- (b) Corresponds to goods and miscellaneous supplies imported by the Company and its Subsidiaries in order to satisfy customers' demand in its pharmacies.

## Notes to the interim consolidated financial statements (continued)

(c) The movement in the provision for inventory impairment for the twelve-month period ended December 31, 2021 and 2020, were as follows:

	2021 S/(000)	2020 S/(000)
<b>Balance at the beginning of the period</b>	<b>15,643</b>	<b>12,525</b>
Provision of the period, Note 17 (a)	7,817	9,998
Recovery	(2,848)	-
Write-off	(6,227)	(7,218)
Foreign currency translation	392	338
<b>Balance at the end of the period</b>	<b>14,777</b>	<b>15,643</b>

The provision for inventory impairment is determined based on stock turnover, discounts granted for the liquidation of the merchandise and other characteristics based on periodic evaluations performed by the Management of the Company and its Subsidiaries.

### 7. Investments at fair value through equity

In August and September 2021, the Company acquired financial investments corresponding to bonds issued by InRetail Consumer, the acquisition value was US\$30,260,000 equivalent to S/124,345,000 maturing in 2028 and accruing annual interest of 3.25 percent and presented in the consolidated statement of cash flow. As of December 31, 2021, these financial instruments amount to US\$30,000,000 equivalent to S/119,250,000.

As of December 31, 2021, the Company has other investments at fair value through equity for an amount of US\$13,322,000 equivalent to S/52,956,000 (US\$14,942,000 equivalent to S/54,061,000 as of December 31, 2020).

The fair value of these instruments is determined by the price quotes published in an active market.

As of December 31, 2021 and December 31, 2020, the unrealized result net of deferred tax is S/13,265,000 and S/14,774,000 respectively and is presented in the consolidated statement of changes in equity.

### 8. Derivative financial instrument

As of December 31, 2021, this item comprises of three contracts of derivative financial instruments (currency) (as of December 31, 2020, one contract of derivative financial instrument). These contracts were designated to hedge cash flows and were recorded at its fair value. The detail of this operation is are follows:

Counterparty	Nominal value US\$(000)	Due	Pay fix at %	Book value of the hedged item S/(000)	Fair value 2021 S/(000)	Fair value 2020 S/(000)
Citibank N.A. (a)	400,000	May-23	1.27	1,449,600	-	112,273
Citibank N.A. (b)	138,000	Mar-28	-	551,724	44,665	-
Citibank N.A. (b)	100,000	Mar-28	1.50	399,800	44,979	-
Citibank N.A. (b)	50,000	Mar-28	1.50	199,900	22,282	-
<b>Total</b>					<b>111,926</b>	<b>112,273</b>

## Notes to the interim consolidated financial statements (continued)

- (a) In March 2021, InRetail Pharma settled the Call Spread early, which maturity was in May 2023 and which hedged the issuance of senior notes by InRetail Pharma up to a value of US\$400,000,000 (see note 13(b)). The early settlement of the derivative included the settlement of the liability created by the financing received from Citibank N.A. for the acquisition of the derivative; as of December 31, 2020, the value of said liability amounted to around US\$9,874,000 (equivalent to around S/35,785,000) (see note 13). As a result of this transaction, a total net expense of S/70,141,000 was generated, which is presented as "Financial expenses from the early settlement of call spread" in the consolidated income statement; see note 18.
- (b) In March 2021, InRetail Pharma S.A., decided to hedge the foreign currency exposure of its US\$288,000,000, Intercompany loan with InRetail Consumer (a related Special Purpose Entity) through a Call Spread structure, see note 19 (c), these instruments cover 100 percent of the exposure in foreign currency of the principal of the issues and protects exchange rate variations between S/3.70 and S/4.20 per US\$1.00.

On September 16, 2021, InRetail Pharma S.A. decided to replace each US\$150,000,000 of its Call Spread with two Range Only Principal Swaps of US\$100,000,000 and US\$50,000,000, on the intercompany loan, which fixed the exchange of currency at the exchange rate of S/4.1045 and S/4.1100 per US\$1.00, respectively and that protects variations in the exchange rate between S/3.70 and S/6.00 per US\$1.00, which for the purposes of IFRS 9, qualifies as an effective hedging instruments.

The substitution of the "Call Spread" for the "Range Only Principal Swaps" allows the hedging objective to be met, therefore, the time value of the instrument substituted at the date of the transaction of S/50,400,000 will be recognized in results on a straight-line basis until the maturity of the hedge. As a result of this transaction, a total net expense of S/8,323,000 was generated as of December 31, 2021. See Note 18.

As a result of this transaction, a total net expense estimated at S/8,323,000 was generated.

From the date of receipt of the loan from the related entity, for the purposes of IFRS 9, it was classified as, see note 19 (c).

## Notes to the interim consolidated financial statements (continued)

### 9. Property, furniture and equipment, net

(a) The table below presents the movement and composition of this item:

	Land	Building infrastructure and facilities	Furniture and fixture	Vehicles	Miscellaneous equipment	Work in progress	Total 2021	Total 2020
	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)
<b>Cost</b>								
<b>Initial balance</b>	<b>257,346</b>	<b>405,422</b>	<b>142,122</b>	<b>1,503</b>	<b>364,326</b>	<b>12,914</b>	<b>1,183,633</b>	<b>1,129,159</b>
Additions (b)	470	70,335	30,129	253	44,998	20,854	167,039	78,446
Sales (c)	-	(10)	(2,486)	-	(3,987)	-	(6,483)	(12,371)
Disposal (c)	-	(6,243)	(4,245)	(111)	(8,132)	-	(18,731)	(12,500)
Disposal of subsidiaries	(27)	(3,112)	(3,616)	(89)	(47,511)	(479)	(54,834)	(4,145)
Transfer	-	9,382	4,480	-	2,866	(16,728)	-	-
Transfer to intangible assets, Note 10(a)	-	-	-	-	-	-	-	(271)
Foreign currency translation	8	477	1,027	(3)	5,896	6	7,411	5,315
<b>Final balance</b>	<b>257,797</b>	<b>476,251</b>	<b>167,411</b>	<b>1,553</b>	<b>358,456</b>	<b>16,567</b>	<b>1,278,035</b>	<b>1,183,633</b>
<b>Accumulated depreciation</b>								
<b>Initial balance</b>	-	<b>238,269</b>	<b>104,508</b>	<b>1,278</b>	<b>269,072</b>	-	<b>613,127</b>	<b>568,466</b>
Additions (d)	-	35,736	10,839	234	36,072	-	82,881	66,832
Sales (c)	-	(7)	(2,333)	-	(3,956)	-	(6,296)	(12,215)
Disposal (c)	-	(5,668)	(3,985)	(111)	(7,699)	-	(17,463)	(10,628)
Disposal of subsidiaries	-	(2,557)	(3,234)	(89)	(38,130)	-	(44,010)	(3,336)
Foreign currency translation	-	352	908	(3)	4,769	-	6,026	4,008
<b>Final balance</b>	-	<b>266,125</b>	<b>106,703</b>	<b>1,309</b>	<b>260,128</b>	-	<b>634,265</b>	<b>613,127</b>
<b>Net book value</b>	<b>257,797</b>	<b>210,126</b>	<b>60,708</b>	<b>244</b>	<b>98,328</b>	<b>16,567</b>	<b>643,770</b>	<b>570,506</b>

(b) Additions for the twelve-month period ended December 31, 2021 and December 31, 2020, correspond mainly to the construction and equipment of new premises for InRetail Pharma Group.

(c) It mainly corresponds to assets sold and to the disposals of unused assets as a result of the process of change of format in some premises and closing of pharmacies. The resulting income or expense has been included in the "Other operating income (expenses) net" of the consolidated income statement, respectively.

## Notes to the interim consolidated financial statements (continued)

- (d) Depreciation expense for the twelve-month period ended December 31, 2021 and 2020, was recorded as follows in the income statement:

	2021 S/(000)	2020 S/(000)
Sales expenses, Note 17 (a)	72,966	54,045
Administrative expenses, Note 17 (a)	8,322	6,600
Cost of sales, Note 17 (a)	1,593	6,187
<b>Balance as of December 31</b>	<b>82,881</b>	<b>66,832</b>

- (e) As of December 31, 2021, the cost and corresponding accumulated depreciation of assets acquired through financial leases amount to approximately S/92,152,000 and S/67,265,000, respectively (S/77,094,000 and S/58,818,000, as of December 31, 2020).
- (f) The InRetail Pharma Group maintains insurance policies on their main assets in accordance with the policies established by Management.

### 10. Intangible assets, net

- (a) The table below presents the movement and composition of this item:

	As of December 31, 2021 S/(000)	As of December 31, 2020 S/(000)
<b>Cost</b>		
<b>Initial balance</b>	<b>867,950</b>	<b>847,734</b>
Additions (c)	43,024	23,206
Disposal and/or sales	(532)	(3,091)
Disposal of subsidiaries	(8,499)	(525)
Transfer from property, plant and equipment, Note 9 (a)	-	271
Foreign currency translation	590	355
<b>Final balance</b>	<b>902,533</b>	<b>867,950</b>
<b>Accumulated amortization</b>		
<b>Initial balance</b>	<b>200,114</b>	<b>142,356</b>
Additions (d)	122,672	58,672
Disposals and/or sales	(510)	(698)
Disposal of subsidiaries	(1,592)	(525)
Foreign currency translation	544	309
<b>Final balance</b>	<b>321,228</b>	<b>200,114</b>
<b>Goodwill</b>		
<b>Initial balance</b>	<b>1,272,634</b>	<b>1,272,634</b>
Additions	-	-
<b>Final balance</b>	<b>1,272,634</b>	<b>1,272,634</b>
<b>Net, book value</b>	<b>1,853,939</b>	<b>1,940,470</b>

## Notes to the interim consolidated financial statements (continued)

- (b) As of December 31, 2021 and December 31, 2020, this item mainly includes the goodwill, related to the acquisition of the Quicorp Group. Purchase price for the acquisition of Quicorp was approximately US\$591,351,000 equivalent to S/1,898,255,000 at the date of acquisition.
- (c) As of December 31, 2021 and December 31, 2020, additions mainly correspond to: (i) disbursements for the acquisition of a commercial software program, a general planning system (ERP) and related licenses; and (ii) disbursements for implementation of software and licenses in new stores of InRetail Group.
- (d) Amortization expense for the twelve-month period ended December 31, 2021 and 2020 has been recorded in the following items of the combined statements:

	<b>2021</b> S/(000)	<b>2020</b> S/(000)
Sales expenses, Note 17 (a)	113,676	51,137
Administrative expenses, Note 17 (a)	8,918	7,116
Cost of sales, Note 17 (a)	78	419
<b>Balance as of December 31</b>	<b>122,672</b>	<b>58,672</b>

### 11. Trade payables

The table below presents the composition of this item:

	<b>As of December 31, 2021</b> S/(000)	<b>As of December 31, 2020</b> S/(000)
Bills payable from purchase of goods	1,473,882	1,458,088
Bills payable from commercial services	198,075	135,507
<b>Total</b>	<b>1,671,957</b>	<b>1,593,595</b>

This item mainly includes the obligations to non-related local and foreign suppliers, denominated in local currency and US Dollars, originated mainly from the acquisition of goods, with current maturities and that do not bear any interest. There have been no liens granted on these obligations.

InRetail Pharma Group offers its suppliers access to an accounts payable service arrangement provided by third party financial institutions. This service allows the suppliers to sell their receivables to the financial institutions in an arrangement separately negotiated by the supplier and the financial institution, enabling suppliers to better manage their cash flow and reduce payment processing costs. InRetail Pharma Group has no direct financial interest in these transactions. All of InRetail Pharma Group's obligations, including amounts due, remain due to its suppliers as stated in the supplier agreements.

## Notes to the interim consolidated financial statements (continued)

### 12. Leases

- a) The InRetail Pharma Group maintains leasing contracts for buildings, facilities and vehicles used for its operations. Leases of buildings and facilities generally have terms of 1 to 5 years, and leases of vehicles have terms of 3 to 4 years. The InRetail Pharma Group's obligations under its leases are guaranteed by the lessor's title of the leased assets.

There are several leases that include extension and termination options and variable payments. The InRetail Pharma Group has also entered into certain leases of premises with terms of 12 months or less and leases of low-value office equipment. The InRetail Pharma Group applies the short-term and low-value lease exemptions for this kind of leases.

- b) The movement of this item for the twelve-month period ended as of December 31, 2021 and December 31, 2020, is as follows:

	<b>Buildings infrastructure and facilities</b>	<b>Vehicles</b>	<b>Total 2021</b>	<b>Total 2020</b>
	S/(000)	S/(000)	S/(000)	S/(000)
<b>Cost</b>				
<b>Initial balance</b>	<b>1,025,621</b>	<b>3,092</b>	<b>1,028,713</b>	<b>920,157</b>
Additions	189,062	969	190,031	118,334
Disposal and/or sales	(219,199)	(465)	(219,664)	(8,848)
Disposal subsidiaries	(25,459)	(109)	(25,568)	(3,271)
Foreign currency translation	4,780	264	5,044	2,341
<b>Final balance</b>	<b>974,805</b>	<b>3,751</b>	<b>978,556</b>	<b>1,028,713</b>
<b>Accumulated depreciation</b>				
<b>Initial balance</b>	<b>454,579</b>	<b>1,284</b>	<b>455,863</b>	<b>235,037</b>
Additions, Note 17 (a)	236,687	856	237,543	228,010
Disposal and/or sales	(218,466)	(378)	(218,844)	(5,995)
Disposal subsidiaries	(8,500)	(52)	(8,552)	(2,380)
Foreign currency translation	1,837	113	1,950	1,191
<b>Final balance</b>	<b>466,137</b>	<b>1,823</b>	<b>467,960</b>	<b>455,863</b>
<b>Net book value</b>	<b>508,668</b>	<b>1,928</b>	<b>510,596</b>	<b>572,850</b>

Depreciation expense for the twelve-month period ended December 31, 2021 and 2020, was recorded as follows in the income statement:

	<b>2021</b>	<b>2020</b>
	S/(000)	S/(000)
Sales expenses, Note 17 (a)	230,480	217,964
Administrative expenses, Note 17 (a)	4,226	5,245
Cost of sales, Note 17 (a)	2,837	4,801
<b>Balance as of December 31</b>	<b>237,543</b>	<b>228,010</b>



## Notes to the interim consolidated financial statements (continued)

- c) The movement of the lease liability item, as of December 31, 2021 and December 31, 2020, is as follows:

	<b>As of December 31, 2021</b>	<b>As of December 31, 2020</b>
	S(000)	S(000)
<b>Initial balance</b>	<b>608,298</b>	<b>671,189</b>
Additions	190,031	118,334
Increase for accrued interest, Note 18	43,347	44,137
Amortization	(285,401)	(256,206)
Disbursements made at the start of the contract	(20)	(4,338)
Disposal	(878)	(2,900)
Disposal subsidiary	(20,254)	(890)
Prepayment rents	(1,827)	286
Exchange rate	31,782	37,501
Foreign currency translation	3,133	1,185
<b>Final balance</b>	<b>568,211</b>	<b>608,298</b>
Current	184,389	159,650
Non-current	383,822	448,648
<b>Final balance</b>	<b>568,211</b>	<b>608,298</b>

Additionally, in the twelve-month period ended as of December 31, 2021 and 2020, interest related to the lease liability of S/43,347,000 and S/44,137,000, respectively, was accrued and is presented under "Financial expenses" in the consolidated financial statement of income. See Note 18.

## Notes to the interim consolidated financial statements (continued)

### 13. Interest-bearing loans and borrowings

(a) The table below presents the composition of this item:

Type of obligation	Original currency	Interest rate %	Final maturity	Original amount		Total		Current		Non-current		
				US\$ (000)	\$ (000)	S/(000)	2021 S/(000)	2020 S/(000)	2021 S/(000)	2020 S/(000)	2021 S/(000)	2020 S/(000)
<b>Senior Notes Unsecured (b)</b>												
Senior Notes Unsecured	PEN	6.438	2025	-	-	385,800	384,413	384,041	-	-	384,413	384,041
Senior Notes Unsecured	USD	5.375	2023	400,000	-	-	-	1,436,872	-	-	-	1,436,872
				<b>400,000</b>	<b>-</b>	<b>385,800</b>	<b>384,413</b>	<b>1,820,913</b>	<b>-</b>	<b>-</b>	<b>384,413</b>	<b>1,820,913</b>
<b>Leasings</b>												
<b>Non related entities</b>												
Banco Santander	PEN	7.650	2022	-	-	874	136	328	136	192	-	136
Banco Santander	PEN	6.920	2022	-	-	545	131	316	131	186	-	130
BBVA Banco Continental	PEN	4.950	2021	-	-	129	-	19	-	19	-	-
				<b>-</b>	<b>-</b>	<b>1,548</b>	<b>267</b>	<b>663</b>	<b>267</b>	<b>397</b>	<b>-</b>	<b>266</b>
<b>Notes and Loans</b>												
<b>Related entities</b>												
Banco Internacional del Perú-Interbank (f)	PEN	4.700	2025	-	-	161,950	-	103,363	-	22,970	-	80,393
Banco Internacional del Perú-Interbank (f)	PEN	3.750	2026	-	-	220,000	218,109	-	-	-	218,109	-
Banco Internacional del Perú-Interbank	PEN	0.400	2021	-	-	35,000	-	35,000	-	35,000	-	-
Banco Internacional del Perú-Interbank	PEN	0.037	2022	-	-	17,900	17,900	-	17,900	-	-	-
<b>Non related entities</b>												
Banco Scotiabank (c)	PEN	4.700	2025	-	-	161,950	-	103,380	-	22,973	-	80,407
Banco Scotiabank (c)	PEN	3.750	2026	-	-	330,000	327,166	-	-	-	327,166	-
Banco de Bogotá	COP	6.030	2023	-	2,900,000	-	-	3,061	-	1,052	-	2,009
Banco BBVA Colombia	COP	6.100	2021	-	89,968	-	-	94	-	94	-	-
Citibank (e)	USD	4.250	2022	10,000	-	-	16,660	30,203	16,660	10,068	-	20,135
Banco Pichincha	USD	7.500	2021	300	-	-	-	1,087	-	1,087	-	-
Banco Scotiabank (c)	PEN	1.280	2022	-	-	15,000	15,000	-	15,000	-	-	-
Banco Scotiabank (c)	PEN	2.350	2022	-	-	21,000	21,000	-	21,000	-	-	-
Banco Scotiabank (c)	PEN	1.980	2022	-	-	15,000	15,000	-	15,000	-	-	-
Banco Scotiabank	PEN	0.700	2021	-	-	21,000	-	21,000	-	21,000	-	-
Banco de Crédito del Perú (d)	PEN	3.090	2022	-	-	20,000	20,000	-	20,000	-	-	-
Banco de Crédito del Perú (d)	PEN	1.170	2022	-	-	30,000	30,000	-	30,000	-	-	-
Banco de Crédito del Perú (d)	PEN	3.500	2022	-	-	60,000	60,000	-	60,000	-	-	-
Banco de Crédito del Perú	PEN	1.070	2021	-	-	8,000	-	8,000	-	8,000	-	-
BBVA Banco Continental	PEN	0.029	2022	-	-	40,000	40,000	-	40,000	-	-	-
Banco Scotiabank	PEN	0.031	2022	-	-	30,000	30,000	-	30,000	-	-	-
Banco Scotiabank	PEN	0.030	2022	-	-	40,000	40,000	-	40,000	-	-	-
BBVA Banco Continental	PEN	3.060	2022	-	-	40,000	40,000	-	40,000	-	-	-
				<b>10,300</b>	<b>2,989,968</b>	<b>1,311,800</b>	<b>890,835</b>	<b>350,188</b>	<b>345,560</b>	<b>167,244</b>	<b>545,275</b>	<b>182,944</b>
<b>Call Spread financing, Note 8</b>												
Citibank N.A.	USD	6.473	2023	18,297	-	-	-	35,785	-	15,977	-	19,808
Citibank N.A.	PEN	Between 8.441 and 8.665	2028	-	-	48,931	46,280	-	5,556	-	40,724	-
				<b>18,297</b>	<b>-</b>	<b>48,931</b>	<b>46,280</b>	<b>35,785</b>	<b>5,556</b>	<b>15,977</b>	<b>40,724</b>	<b>19,808</b>
<b>Other obligations (h)</b>												
Hewlett Packard S.A.	USD	Between 2.850 and 4.360	2024 and 2026	8,549	-	-	27,348	16,316	7,521	6,253	19,827	10,063
				<b>8,549</b>	<b>-</b>	<b>-</b>	<b>27,348</b>	<b>16,316</b>	<b>7,521</b>	<b>6,253</b>	<b>19,827</b>	<b>10,063</b>
<b>Total</b>				<b>437,146</b>	<b>2,989,968</b>	<b>1,748,079</b>	<b>1,349,143</b>	<b>2,223,865</b>	<b>358,904</b>	<b>189,871</b>	<b>990,239</b>	<b>2,033,994</b>

## Notes to the interim consolidated financial statements (continued)

- (b) In May 2018, the Company issued debt instruments ("Notes") denominated in US Dollars through a private offer to institutional investors under Rule 144 A and Regulation S, for US\$400,000,000, equivalent to S/1,449,600,000 as of December 31, 2020 that accrues an interest of 5.375 percent annual, with a maturity of 5 years and with semiannual payments of interest and the principal in a single installment upon maturity of the securities. This borrowing was recorded in the consolidated financial statement at amortized cost to an effective interest rate of 5.778 percent, after considering the respective up-front fees that amounted to US\$3,512,000 equivalent to approximately S/12,728,000 as of December 31, 2020. In March 2021, the "Senior Notes Unsecured" were prepaid in full.

As indicated in note 8 (a), the Call Spread related to these bonds was settled early in March 2021.

Additionally, in May 2018, the Company issued debt instruments ("Notes") denominated in Soles for S/385,800,000 that bear an annual interest rate of 6.438 percent, with a maturity of 7 years and with semiannual interest payments and the principal in a single installment upon maturity of the securities. This borrowing was recorded in the consolidated financial statement at amortized cost to an effective interest rate of 6.559 percent, after considering the respective up-front fees that amounted to S/1,387,000 as of December 31, 2021 (S/1,759,000 as of December 31, 2020).

As a result of these issues, InRetail Pharma must comply, until their maturity and full payment, with certain obligations and covenants.

In the opinion of Management, these covenants do not limit the operations of the Company and its Subsidiaries and have been complied satisfactorily and are within the agreed limits as of December 31, 2021 and December 31, 2020. Likewise, 100 percent of the "Senior Notes Unsecured" is guaranteed by the shares of InRetail Pharma S.A. and Subsidiaries.

- (c) Scotiabank Perú  
Química Suiza S.A.C.  
It corresponds to three loans of S/15,000,000, S/15,000,000 and S/21,000,000 with maturity in January 2022, February 2022 and March 2022. The annual accrued interest rates are 1.98, 1.28 and 2.35 percent. There are no specific guarantees.

InRetail Pharma S.A.

It corresponds to one loan amounting of S/161,950,000. The annual accrued interest rate is 4.70 percent with maturity in April 2025, and quarterly payments. This borrowing was recorded in the consolidated financial statement at amortized cost to an effective interest rate of 4.775 percent, after considering the respective up-front fees that amounted of S/731,000 as of December 31, 2020. InRetail Pharma S.A. amortized the debt for the amount of S/57,839,000 as of December 31, 2020. In March 2021, the loan was fully paid.

In March, 2021, the company obtained a loan for S/330,000,000 that accrues an annual nominal interest of 3.750 percent maturing in March 2026, payable in quarterly installments. Said loan is recorded at its amortized cost at an effective annual rate of 4.031 percent, after considering the additional charges of S/2,834,000 as of December 31, 2021.

- (d) Banco de Crédito del Perú  
Química Suiza S.A.C.  
Corresponds to two loans of S/20,000,000 and S/30,000,000 with maturity in February 2021 and March 2022. The annual accrued interests rate are 1.170 and 3.090 percent. There are no specific guarantees.

## Notes to the interim consolidated financial statements (continued)

InRetail Pharma S.A.

Corresponds to one loan of S/60,000,000 with maturity in January 2022. The annual accrued interests rate is 3.500 percent. There is no specific guarantees.

(e) Citibank

Quifatex S.A.

It corresponds to one loan amounting to US\$10,000,000 with maturity in April 2022 and accrued interest rate of 4.250 percent annual.

(f) Banco Internacional del Perú-Interbank

InRetail Pharma S.A.

Corresponds to a loan granted for S/161,950,000 that accrues an annual nominal interest of 4.70 percent, with maturity in April 2025, payable quarterly. This loan is recorded at amortized cost at an effective rate of 4.775 percent, after considering the initial charges of S/748,000 as of December 31, 2020. The Company amortized the debt for the amount of S/57,839,000 as of December 31, 2020. In March 2021, was paid fully.

In March 2021, the company obtained a loan for S/220,000,000 that accrues an annual nominal interest of 3.750 percent maturing in March 2026, payable in quarterly installments. Said loan is recorded at its amortized cost at an effective annual rate of 4.031 percent, after considering the additional charges of S/1,891,000 as of December 31, 2021.

(g) Corresponds to the debt acquired with Hewlett Packard S.A., for the purchase and leasing of computer equipment. These contracts do not have specific guarantees.

(h) During the twelve-month period ended December 31, 2021 and 2020, loans and borrowings accrued interests are recorded in the "Financial expenses" item of the consolidated income statement, see Note 18. Also, as of December 31, 2021 and December 31, 2020, there are interests payable which are recorded in the "Other payables" item of the consolidated statements of financial position.

(i) Some of the interest-bearing loans and borrowings include standard clauses requiring the InRetail Pharma Group to meet financial ratios, use of funds criteria and other administrative matters. In Management's opinion, as of December 31, 2021 and December 31, 2020, standard clauses do not limit the normal operation of the InRetail Pharma Group and have been fulfilled.

(j) Financial obligations are payable as follows:

	<b>2021</b>	<b>2020</b>
	S/ (000)	S/ (000)
2021	-	189,871
2022	358,904	84,775
2023	13,341	1,492,184
2024	13,117	72,994
2025	667,513	384,041
2026 onwards	296,268	-
<b>Total</b>	<b>1,349,143</b>	<b>2,223,865</b>

## Notes to the interim consolidated financial statements (continued)

### 14. Income tax

- (a) The amounts presented in the statement of financial position as of December 31, 2021 and December 31, 2020, as well as the consolidated income statements for the twelve-month period ended December 31, 2021 and 2020 are shown below:

Statements of financial position	As of December 31, 2021		As of December 31, 2020	
	Assets S/(000)	Liabilities S/(000)	Assets S/(000)	Liabilities S/(000)
InRetail Pharma S.A.	30,889	-	25,882	-
Eckerd Amazonia S.A.C.	-	-	861	-
Boticas del Oriente S.A.C.	-	-	673	-
Química Suiza S.A.C.	-	47,065	-	48,915
Cifarma S.A.C.	-	-	852	-
Vanttive S.A.C.	44	-	46	-
Droguería InRetail Pharma S.A.C.	2,780	-	1,793	-
Quicorp S.A.	20	-	931	-
Quifatex S.A.	8,740	-	8,201	-
Vanttive Cía. Ltda.	128	-	101	-
Farmacías Peruanas S.A.C.	4,668	-	136	-
Quimiza Ltda.	927	-	766	-
Química Suiza Colombia S.A.S. (formerly Quideca S.A.)	-	-	766	-
Mifarma S.A.C.	42,858	-	26,337	-
Boticas IP S.A.C.	18,501	-	-	-
Albis S.A.C.	-	-	16,047	-
Jorsa de la Selva S.A.C.	2,785	-	1,495	-
Consolidation adjustment	-	120,022	-	157,601
<b>Total</b>	<b>112,340</b>	<b>167,087</b>	<b>84,887</b>	<b>206,516</b>

Statements of comprehensive income	Income tax for the twelve-months period ended December 31, 2021 and 2020	
	2021 S/(000)	2020 S/(000)
Current	(200,914)	(198,285)
Deferred	63,515	56,827
<b>Income tax expense</b>	<b>(137,399)</b>	<b>(141,458)</b>

- (b) As of December 31, 2021 and December 31, 2020, the liability for income tax, net of the advanced tax, amounted to approximately S/6,026,000 and S/72,855,000, respectively. Also, as of December 31, 2021 and December 31, 2020, the income tax credit amounted to approximately S/119,131,000 and S/77,854,000, respectively.

### 15. Equity

- (a) Capital stock

As of December 31, 2021 and December 31, 2020, the capital stock of the Company is represented by 15,839,379 common shares, with a nominal value of S/1.00 each, which are entirely authorized and paid.

## Notes to the interim consolidated financial statements (continued)

(b) Capital premium

Corresponds to cash contributions for a total amount of approximately S/4,182,000. In accordance with the agreements of the General Shareholders Meetings of July 2008, an amount of S/791,000 was recorded as capital stock and the difference of approximately S/3,391,000 was recorded as a capital premium, which is presented in the item "Capital premium" in the consolidated statement of financial position.

In April 2018, the merger by absorption of IR Pharma S.A.C., generated an exchange of shares for an equity received of S/481,500,000, issuing shares of S/2,056,000 and recognizing a capital premium of S/479,444,000.

(c) Legal reserve

As of December 31, 2021 and December 31, 2020, this item includes the legal reserve established by the Company and its Subsidiaries. As provided in the General Corporations Law, it is required that a minimum of 10 percent of distributable income for each year is transferred to a legal reserve until such reserve equals 20 percent of the capital. The legal reserve can absorb losses or be capitalized, in both cases it must be replenished. The legal reserve is appropriated when the General Shareholders' Meeting approves it.

(d) Distribution of dividends

At the General Shareholders' Meeting held in October, November and December 2021, the distribution of dividends was approved for a value of S/190,000,000, which was paid during the fourth quarter.

At the General Shareholders' Meeting of InRetail Pharma S.A. held in July, August and September 2021, the distribution of dividends was approved for a value of S/105,000,000, which was paid during the third quarter.

At the General Shareholders' Meeting of InRetail Pharma S.A. held on April 30, 2021, the distribution of dividends was approved for a value of S/315,000,000, which was paid on May 3, 2021.

At the General Shareholders' Meeting of InRetail Pharma S.A. held in February 2021, dividend distributions for a total of S/39,000 were approved.

At the General Shareholders' Meetings of InRetail Pharma S.A. held on February 10, 2020, April 30, 2020, August 27, 2020 and December 21, 2020 it was approved, the dividend distribution of S/79,013,000, S/60,349,000, S/30,000,000 and S/40,000,000, respectively.

### 16. Tax Situation

- (a) The Company and its Subsidiaries domiciled in Peru, Ecuador, Bolivia y Colombia, are subject to the tax regime of each country and calculate the income tax based on their individual financial statements. As of December 31, 2021 and December 31, 2020, the income tax rate was:

Country	%
Peru	29.5
Ecuador	25.0
Bolivia	25.0
Colombia	31.0

## Notes to the interim consolidated financial statements (continued)

(b) Entities and individuals not domiciled in Peru must pay an additional tax over dividends received. In this regard, attention to Legislative Decree N° 1261, the additional tax on dividend income generated is as follows:

- 4.1 percent for the profits generated until December 31, 2014.
- 6.8 percent for the profits generated in the years 2015 and 2016.
- 5.0 percent for the profits generated since January 1, 2017.

(c) Law No. 29663, later amended by law No. 29757, established Peruvian source income as that obtained by the indirect sales of shares representing the capital stock of companies domiciled in the country.

To this end, an indirect transference is configured when the following two assumptions occur together:

- (i) In first place, 10 percent or more of shares of the non domiciled company must be sold in a period of twelve months.
- (ii) In second place, the market value of the Peruvian company's shares must represent 50 percent or more of the market value of the non domiciled company, in a period of twelve months.

(d) For purposes of determining the Income Tax, transfer pricing of transactions with related companies and companies domiciled in territories with low or no taxation must be supported with documentation and information on assessment methods applied and criteria considered. Based on the analysis of the operations of the InRetail Pharma Group, Management and its legal advisors consider that as consequence of the application of the regulation in force, there will not be any significant contingencies for the InRetail Pharma Group as of December 31, 2021 and December 31, 2020.

(e) The tax authority is legally entitled to review and, if necessary, adjust the Income Tax computed. Following are the years subject to review by the tax authority of the Subsidiaries of InRetail Pharma S.A. incorporated in Peru and foreign:

	<b>Income Tax</b>	<b>Value added tax</b>
InRetail Pharma S.A.	From 2016 to 2021	From 2017 to 2021
Eckerd Amazonía S.A.C.	From 2016 to 2021	From 2017 to 2021
Boticas del Oriente S.A.C.	From 2016 to 2021	From 2017 to 2021
Quicorp S.A.	From 2016 to 2021	From 2017 to 2021
Química Suiza Comercial S.A.C.	From 2016 to 2018	From 2017 to 2018
Vanttive S.A.C.	From 2016 to 2021	From 2017 to 2021
Vanttive Cía. Ltda.	From 2016 to 2021	From 2016 to 2021
Química Suiza S.A.C.	From 2017 to 2021	From 2017 to 2021
Quifatex S.A.	From 2019 to 2021	From 2019 to 2021
Quimiza Ltda.	From 2015 to 2021	From 2015 to 2021
Jorsa de la Selva S.A.C.	From 2016 to 2021	From 2017 to 2021
Mifarma S.A.C.	From 2017 to 2021	From 2017 to 2021
Albis S.A.C.	From 2016 to 2021	From 2017 to 2021
Droguería InRetail Pharma S.A.C.	From 2019 to 2021	From 2019 to 2021
Farmacias Peruanas S.A.C.	From 2020 to 2021	From 2020 to 2021
Botica Torres de Limatambo S.A.C.	From 2017 to 2018	From 2017 to 2018
Droguería La Victoria S.A.C.	From 2016 to 2018	From 2017 to 2018
Boticas IP S.A.C	2021	2021
Farmacias Peruanas S.A.	From 2017 to 2018	From 2017 to 2018

## Notes to the interim consolidated financial statements (continued)

Due to possible interpretations that the tax authority may give to legislation, it is not possible to determine, to date, whether the reviews will result in liabilities for the InRetail Pharma Group. Therefore, any major tax or surcharge that may result from eventual revisions by the tax authority would be charged to the consolidated statements of comprehensive income of the period in which such tax or surcharge is determined.

In opinion of Management of the InRetail Pharma Group as well as its legal advisor's opinion, any eventual additional tax settlement would not be significant to the consolidated financial statements as of December 31, 2021 and December 31, 2020.

- (f) As of December 31, 2021 and December 31, 2020, estimated losses from previous periods for Subsidiaries for tax purposes are the following:

	<b>As of December 31, 2021</b>	<b>As of December 31, 2020</b>
	S/(000)	S/(000)
Albis S.A.C.	-	39,395
InRetail Pharma S.A.	20,839	-
Quicorp S.A.	-	3,155
<b>Total</b>	<b><u>20,839</u></b>	<b><u>42,550</u></b>

According to the Income Tax Act and its amendments, entities domiciled in Peru have the faculty to choose one of the following methods to draw their tax losses:

- (i) The tax loss can be offset with future profits until its final extinction by applying said loss to up to 50 percent of the taxable income; or
- (ii) The tax loss can be used for four years after it has been generated.

Albis S.A.C. and Quicorp S.A. have chosen method (i) and InRetail Pharma S.A. the method (ii).

### 17. Operating expenses

- (a) The table below presents the components of this item for the twelve-month period ended December 31, 2021 and 2020:

	<b>2021</b>	<b>2020</b>
	S/(000)	S/(000)
Cost of sales	5,578,665	4,992,245
Selling expenses	1,494,405	1,271,772
Administrative expenses	301,698	287,583
<b>Total</b>	<b><u>7,374,768</u></b>	<b><u>6,551,600</u></b>

The table below presents the components of operating expenses included in cost of sales, sales and administrative expenses items.



## Notes to the interim consolidated financial statements (continued)

	2021			
	Cost of sales	Selling expenses	Administrative expenses	Total
	S/(000)	S/(000)	S/(000)	S/(000)
Initial balance of goods, Note 6 (a)	1,091,368	-	-	1,091,368
Initial balance of raw material, Note 6 (a)	19,552	-	-	19,552
Initial balance of supplies, Note 6 (a)	550	-	-	550
Initial balance of finished goods, Note 6 (a)	455	-	-	455
Purchase of goods and supplies	5,656,942	-	-	5,656,942
Final balance of goods, Note 6 (a)	(1,235,924)	-	-	(1,235,924)
Final balance of raw materials, Note 6 (a)	(860)	-	-	(860)
Final balance of supplies, Note 6 (a)	(874)	-	-	(874)
Impairment of inventories, Note 6 (c)	7,817	-	-	7,817
Factory overhead	4,702	-	-	4,702
Personnel expenses	-	667,051	175,914	842,965
Depreciation, Note 9 (d)	1,593	72,966	8,322	82,881
Depreciation of right-of-use asset, Note 12 (b)	2,837	230,480	4,226	237,543
Amortization, Note 10 (d)	78	113,676	8,918	122,672
Services provided by third parties (b)	-	253,563	68,647	322,210
Advertising	-	53,616	15	53,631
Packing and packaging	-	8,252	746	8,998
Rental of premises	-	8,490	11	8,501
Low-value asset leases	50	15,109	805	15,964
Taxes	-	10,817	12,637	23,454
Provision for doubtful trade receivables, Note 5(d)	-	8,203	61	8,264
Provision for doubtful other account receivables	-	707	1,478	2,185
Recoveries of provision trade account receivables, Note 5(d)	-	(2,496)	-	(2,496)
Recovery of provision other account receivables	-	(327)	-	(327)
Insurance	-	12,009	886	12,895
Other charges (c)	30,379	42,289	19,032	91,700
<b>Total</b>	<b>5,578,665</b>	<b>1,494,405</b>	<b>301,698</b>	<b>7,374,768</b>

  

	2020			
	Cost of sales	Selling expenses	Administrative expenses	Total
	S/(000)	S/(000)	S/(000)	S/(000)
Initial balance of goods	997,569	-	-	997,569
Initial balance of raw material	15,204	-	-	15,204
Initial balance of supplies	1,008	-	-	1,008
Initial balance of finished goods	189	-	-	189
Purchase of goods	5,013,807	-	-	5,013,807
Final balance of goods	(1,091,368)	-	-	(1,091,368)
Final balance of raw materials	(19,552)	-	-	(19,552)
Final balance of supplies	(550)	-	-	(550)
Final balance of finished goods	(455)	-	-	(455)
Impairment of inventories, Note 6 (c)	9,998	-	-	9,998
Factory overhead	39,363	-	-	39,363
Personnel expenses	-	584,468	202,326	786,794
Depreciation, Note 9 (d)	6,187	54,045	6,600	66,832
Depreciation of right-of-use asset, Note 12 (b)	4,801	217,964	5,245	228,010
Amortization, Note 10 (d)	419	51,137	7,116	58,672
Services provided by third parties (b)	-	215,661	42,853	258,514
Advertising	-	36,390	4	36,394
Packing and packaging	-	10,142	978	11,120
Rental of premises	1,151	30,438	813	32,402
Taxes	-	8,683	5,914	14,597
Provision for doubtful trade receivables, Note 5(d)	-	8,827	-	8,827
Provision for doubtful other account receivables	-	1,317	-	1,317
Recovery of provision for doubtful other account receivables	-	(1,482)	(32)	(1,514)
Recovery of provision for doubtful trade receivables, Note 5(d)	-	(4)	(16)	(20)
Insurance	-	10,524	924	11,448
Other charges (c)	14,474	43,662	14,858	72,994
<b>Total</b>	<b>4,992,245</b>	<b>1,271,772</b>	<b>287,583</b>	<b>6,551,600</b>

## Notes to the interim consolidated financial statements (continued)

- (b) Corresponds mainly to expenses of electricity, water, telephone, premises maintenance services and transport services.
- (c) Mainly includes general expenses in stores.

### 18. Financial expenses

- (a) The table below presents the components of financial expenses:

	<b>2021</b>	<b>2020</b>
	S/(000)	S/(000)
Expenses for early settlement of "Call Spread" (e)	78,464	-
Premium for early cancelation of senior notes (c)	47,530	-
Interest on loans, borrowings and bonds payable	66,766	119,983
Interest on loans with related parties, Note 19 (c)	40,042	-
Interest on lease liability, Note 12 (c)	43,347	44,137
Accrual of structuring cost of financial obligation	4,079	5,434
Accrual of structuring cost of Senior Notes (d)	13,105	-
Interest from derivative instruments "Call Spread"	3,771	2,734
Premium accrual of "Call Spread"	15,595	12,623
Other financial expenses	5,441	5,558
<b>Total</b>	<b>318,140</b>	<b>190,469</b>

- (b) As of December 31, 2021 and December 31, 2020, there are interest payable for these obligations for approximately S/7,352,000 and S/19,087,000, respectively, which are recorded in the "Other payables" item of the consolidated statements of financial position.
- (c) As of December 31, 2021, includes the premium corresponding to the early redemption of the "Senior Notes Unsecured" issued by InRetail Pharma S.A. in US Dollars for US\$12,794,000 equivalent to S/47,530,000.
- (d) As of December 31, 2021, corresponds mainly to the accrual of the structuring costs related to the early redemption of the "Senior Notes Unsecured" issued by InRetail Pharma S.A. in (i) US Dollars for US\$3,284,000 equivalent to S/12,837,000 y (ii) Soles S/268,000.
- (e) As of December 31, 2021, it corresponds to the transfer of the value over time of other comprehensive income to income for the period, related to the early settlement of the "Call Spread". See Note 8(a).

## Notes to the interim consolidated financial statements (continued)

### 19. Transactions with related parties

(a) The following table provides the total amount of transactions that have been entered into with related parties for the twelve-month period ended as of December 31, 2021 and 2020:

	<b>2021</b> S/(000)	<b>2020</b> S/(000)
<b>Income</b>		
Sales	34,045	33,385
Rendering of services	3,621	1,906
Interest income	-	3,065
Dividend income	2,035	-
Others	676	1,872
<b>Total</b>	<b>40,377</b>	<b>40,228</b>
<b>Expenses</b>		
Renting of premises and land	15,633	3,995
Reimbursement of expenses	5,529	8,175
Minor services	13,746	6,018
Interest	40,042	-
Others	4,740	11,661
<b>Total</b>	<b>79,690</b>	<b>29,849</b>

(b) As a result of the transactions with related companies, the InRetail Pharma Group recorded the following balances as of December 31, 2021 and December 31, 2020:

	<b>As of December 31,</b> <b>2021</b> S/(000)	<b>As of December 31,</b> <b>2020</b> S/(000)
<b>Receivables</b>		
Real Plaza S.A.	-	39
Supermercados Peruanos S.A. (e)	8,639	6,662
Homecenters Peruanos S.A. (e)	325	214
Homecenters Oriente S.A.C. (e)	15	10
Agora Servicios Digitales S.A.C.	1	35
Tiendas Peruanas S.A.	69	23
Financiera Oh! S.A.	1,114	510
InDigital XP S.A.C.	1	-
Makro Supermayorista S.A.	17	-
Plaza Vea Oriente S.A.C. (e)	3	181
Other	157	261
<b>Total</b>	<b>10,341</b>	<b>7,935</b>

## Notes to the interim consolidated financial statements (continued)

	As of December 31, 2021 S/(000)	As of December 31, 2020 S/(000)
<b>Payables</b>		
Homecenters Peruanos S.A.	33	155
InRetail Perú Corp.	19	-
Plaza Vea Oriente S.A.C.	114	-
Financiera Oh! S.A.	3,004	454
Agora Servicios Digitales S.A.C.	17	179
Homecenters Oriente S.A.C.	1	-
Real Plaza S.A.	78	272
Inmobiliaria Puerta del Sol S.A.	25	99
Makro Supermayorista S.A.	17	-
Supermercados Peruanos S.A.	576	1,164
IR Management S.R.L.	950	458
InRetail Consumer (c)	1,416,779	-
Interproperties Perú	191	953
InDigital XP S.A.C.	603	51
Other	233	296
<b>Total</b>	<b>1,422,640</b>	<b>4,081</b>
Remunerations payable to key management	-	-
<b>Total</b>	<b>1,422,640</b>	<b>4,081</b>
Current portion	20,057	4,081
Non-current portion	1,402,583	-
<b>Total</b>	<b>1,422,640</b>	<b>4,081</b>

The policy of the InRetail Pharma Group is to make transactions with related companies at terms equivalent to those that prevail in arm's length transactions.

- (c) In March 2021, InRetail Consumer (Special Purpose Entity) related entity, granted a loan of US\$288,000,000 (equivalent to S/1,151,424,000 as of December 31, 2021) and S/266,400,000, said obligations were registered in the consolidated financial statements at amortized cost at an annual effective interest rate of 3.453 and 5.118 percent, respectively, after considering the respective initial charges of approximately US\$3,048,000 (equivalent to a total of approximately S/12,187,000) and S/3,054,000, respectively.

As of December 31, 2021, an interest of S/40,042,000 was accrued, which was recorded in the item "Financial expenses" of the consolidated statement of comprehensive income. Likewise, as of December 31, 2021, accumulated interest payable of S/14,196,000 is maintained.

The funds obtained from the loan were used, mainly, for the early payment of the "Senior Notes Unsecured".

## Notes to the interim consolidated financial statements (continued)

- (d) Outstanding balances at period-end are unsecured and interest free, except for the financial obligations explained in this note. There have been no guarantees provided or received for any related party receivables or payables. As of December 31, 2021 and December 31, 2020, the InRetail Pharma Group has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year by examining the financial position of the related party and the market in which the related party operates.
- (e) Corresponds to the balances pending for the sale of goods of Química Suiza S.A.C. as of December 31, 2021.
- (f) The compensation of key management personnel of the InRetail Pharma Group for the twelve-month period ended December 31, 2021 and 2020, is detailed below:

	<b>2021</b> S/(000)	<b>2020</b> S/(000)
Short term employee benefits	28,422	30,529
Insurance and medical benefits	64	43
Employment benefits for contract termination	-	1,048
<b>Total</b>	<b>28,486</b>	<b>31,620</b>

- (g) As of December 31, 2021 and December 31, 2020, the InRetail Pharma Group maintains the following balances in the cash and cash equivalent items:

	<b>2021</b> S/(000)	<b>2020</b> S/(000)
Banco Internacional del Peru – Interbank S.A.A.	50,844	199,354

## Notes to the interim consolidated financial statements (continued)

### 20. Earnings per share

Basic earnings per share amounts are calculated by dividing profit for the twelve-month period attributable to ordinary equity holders of InRetail Pharma S.A. by the weighted average number of ordinary shares outstanding during the same period. As there are no dilutive instruments outstanding, basic and diluted earnings per share are identical.

The following reflects basic and diluted earnings per share computations:

	<b>Ordinary shares</b>		
	<b>Outstanding shares</b>	<b>Effective days until period-end</b>	<b>Weighted average of shares</b>
Number as of January 1, 2020	15,839,379	365	15,839,379
Number as of December 31, 2020	15,839,379		15,839,379
Number as of January 1, 2021	15,839,379	365	15,839,379
Number as of December 31, 2021	15,839,379		15,839,379
	<b>For the twelve-months period ended December 31, 2021</b>		
	<b>Net income (numerator)</b>	<b>Shares (denominator)</b>	<b>Earnings per share</b>
	<i>S/</i>		<i>S/</i>
Basic and diluted earnings per share	221,344,000	15,839,379	13.974
	<b>For the twelve-months period ended December 31, 2020</b>		
	<b>Net income (numerator)</b>	<b>Shares (denominator)</b>	<b>Earnings per share</b>
	<i>S/</i>		<i>S/</i>
Basic and diluted earnings per share	282,561,000	15,839,379	17.839

There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of completion of these consolidated financial statements.

## Notes to the interim consolidated financial statements (continued)

### 21. Commitments and contingencies

#### Commitments

The main commitments assumed are presented below:

- (a) As of December 31, 2021, the Company and its Subsidiaries agreed with several financial entities on the issuance of solidary and irrevocable letters of guarantee for approximately S/54,711,000, US\$8,053,000, and B\$237,000 (S/53,844,000, US\$2,812,000 and B\$104,000 as of December 31, 2020), respectively, to comply with the payment of goods purchased to foreign suppliers.

#### Contingencies

- (a) InRetail Pharma S.A., Albis S.A.C., Química Suiza S.A.C., Mifarma S.A.C., Jorsa de la Selva S.A.C. and Vantive S.A.C. maintain various claims for civil, labor and tax processes for an approximate total amount of S/54,534,000. In the opinion of Management and its legal advisors, said processes should be resolved favorably for these components, in opinion of Management, it is not necessary to record additional liabilities for these items as of December 31, 2021 and 2020.
- (b) Eckerd Amazonía S.A.C. is in the process of claiming against the Tax Authority for determinations of debts and fines related to VAT for the period between January 2003 and September 2005 for an approximate amount of S/17,943,000. In opinion of Management and its legal advisors these contingencies are stated as possible, and significant liabilities will not arise as result of this contingency as of December 31, 2021 and December 31, 2020. In July 2021, the tax court issued an unfavorable resolution to the Company for which a payment of S/17,943,000 has been made and recognized an expense of S/9,658,0000, the Company will continue with the claim.

### 22. Business segments

For management purposes, the InRetail Pharma Group is organized into business units based on their products and services and has two reportable segments as follows:

- The pharmacies segment is a nationwide supplier of drugs, medicines and cosmetic related products through the chains of pharmacies named "Inkafarma" and "Mifarma".
- Manufacturing, Distribution and Marketing segment operates nationally and internationally.

Management monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on operating profit or loss and is measured consistently with operating profit or loss in the consolidated financial statements.

Transfer prices between operating segments are on an arm's length basis in a manner similar to transactions with third parties.

As of December 31, 2021 and December 31, 2020, and for the twelve-month period ended December 31, 2021 and 2020, InRetail Pharma S.A. is organized into two main business lines. Transactions between the business segments are carried out under normal commercial terms and conditions. The following table presents the financial information of InRetail Pharma Group by business segments for the twelve-month period ended December 31, 2021 and 2020

	Pharmacies S/(000)	Manufacturing, Distribution and Marketing S/(000)	Total segments S/(000)	Holding accounts, consolidation adjustments and intercompany eliminations S/(000)	Consolidated S/(000)
<b>For the twelve-month period ended December 31, 2021</b>					
<b>Revenue</b>					
External income	5,983,767	2,080,721	8,064,488	-	8,064,488
Inter-segment	34,405	669,822	704,227	(704,227)	-
<b>Total revenue</b>	<b>6,018,172</b>	<b>2,750,543</b>	<b>8,768,715</b>	<b>(704,227)</b>	<b>8,064,488</b>
<b>Cost of sales</b>					
Cost of sales	(3,837,026)	(1,741,639)	(5,578,665)	-	(5,578,665)
Inter-segment	(29,812)	(669,985)	(699,797)	699,797	-
<b>Gross profit</b>	<b>2,151,334</b>	<b>338,919</b>	<b>2,490,253</b>	<b>(4,430)</b>	<b>2,485,823</b>
<b>Selling expenses</b>					
Selling expenses	(1,222,391)	(175,225)	(1,397,616)	(96,789)	(1,494,405)
<b>Administrative expenses</b>					
Administrative expenses	(230,584)	(72,188)	(302,772)	1,074	(301,698)
<b>Other operating income, net</b>					
Other operating income, net	7,722	3,851	11,573	(3,959)	7,614
<b>Operating profit</b>	<b>706,081</b>	<b>95,357</b>	<b>801,438</b>	<b>(104,104)</b>	<b>697,334</b>
<b>Exchange difference, net</b>					
Exchange difference, net	(34,228)	5,268	(28,960)	-	(28,960)
<b>Financial income</b>					
Financial income	216,454	174,234	390,688	(382,179)	8,509
<b>Financial expenses</b>					
Financial expenses	(311,234)	(7,398)	(318,632)	492	(318,140)
<b>Profit before income tax</b>	<b>577,073</b>	<b>267,461</b>	<b>844,534</b>	<b>(485,791)</b>	<b>358,743</b>
<b>Income tax expense</b>					
Income tax expense	(138,221)	(29,912)	(168,133)	30,734	(137,399)
<b>Profit for the year</b>	<b>438,852</b>	<b>237,549</b>	<b>676,401</b>	<b>(455,057)</b>	<b>221,344</b>



Notes to the interim consolidated financial statements (continued)

	Pharmacies	Manufacturing, Distribution and Marketing S/(000)	Total segments S/(000)	Holding accounts, consolidation adjustments and intercompany eliminations S/(000)	Consolidated S/(000)
<b>For the twelve-month period ended December 31, 2020</b>					
<b>Revenue</b>					
External income	5,297,283	1,894,200	7,191,483	-	7,191,483
Inter-segment	35,731	630,905	666,636	(666,636)	-
<b>Total revenue</b>	<b>5,333,014</b>	<b>2,525,105</b>	<b>7,858,119</b>	<b>(666,636)</b>	<b>7,191,483</b>
Cost of sales	(3,418,225)	(1,574,020)	(4,992,245)	-	(4,992,245)
Inter-segment	(25,989)	(636,051)	(662,040)	662,040	-
<b>Gross profit</b>	<b>1,888,800</b>	<b>315,034</b>	<b>2,203,834</b>	<b>(4,596)</b>	<b>2,199,238</b>
Selling expenses	(1,062,312)	(174,375)	(1,236,687)	(35,085)	(1,271,772)
Administrative expenses	(214,081)	(75,363)	(289,444)	1,861	(287,583)
Other operating income (expenses), net	9,817	(334)	9,483	-	9,483
<b>Operating profit</b>	<b>622,224</b>	<b>64,962</b>	<b>687,186</b>	<b>(37,820)</b>	<b>649,366</b>
Exchange difference, net	(43,857)	(652)	(44,509)	-	(44,509)
Financial income	102,463	94,981	197,444	(187,813)	9,631
Finance expenses	(182,529)	(17,219)	(199,748)	9,279	(190,469)
<b>Profit before income tax</b>	<b>498,301</b>	<b>142,072</b>	<b>640,373</b>	<b>(216,354)</b>	<b>424,019</b>
Income tax expense	(124,193)	(17,153)	(141,346)	(112)	(141,458)
<b>Profit for the year</b>	<b>374,108</b>	<b>124,919</b>	<b>499,027</b>	<b>(216,466)</b>	<b>282,561</b>

Inter-segment revenues are eliminated upon consolidation and reflected also in the “Adjustments and eliminations” column.

**Geographic information-**

As of December 31, 2021 and December 31, 2020, the operations of all the Company's subsidiaries are mainly carried out in Peru; with income and assets from abroad not being significant at those dates.

**23. Fair value**

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

When a financial instrument is traded in an active and liquid market, its quoted market price in an actual transaction provides the best evidence of its fair value. When a quoted market price is not available, or may not be indicative of the fair value of the financial instrument, other estimation techniques may be used to determine such fair value, including the current market value of another financial instrument that is substantially similar, discounted cash flow analysis or other techniques applicable, all of which are significantly affected by the assumptions used. Although Management uses its best judgment in estimating the fair value of these financial instruments, there isn't an exact estimation technique. As a result, the fair value may not be indicative of the net realizable of settlement value.

The following methods and assumptions were used to estimate the fair values:

(a) Financial instruments whose fair value is similar to book value

Assets and liabilities that are liquid or have short maturities (less than three months), such as cash and short-term deposits, trade and other receivables, trade and other payables and other current liabilities, approximate to their carrying amounts largely due to the short-term maturities of these instruments. Also, the derivative instrument by the InRetail Pharma Group is recorded at fair value.

(b) Fixed-rate financial instruments

The fair value of financial assets and liabilities at fixed interest rates and amortized cost is determined by comparing market interest rates at their initial recognition to current market rates related to similar financial instrument. The estimated fair value of interest-bearing deposits is determined through discounted cash flows by using market interest rates in the prevailing currency with similar maturities and credit risks.

(c) Investment at fair value through equity

Fair value of investment at fair value through equity is derived from quoted market prices in active markets, if available. Fair value of unquoted investment at fair value through equity is estimated using a discounted cash flow technique.

## Notes to the interim consolidated financial statements (continued)

### Fair value hierarchy

The InRetail Pharma Group uses the following hierarchy for determining and disclosing the fair value of its financial instrument recorded in the statement of financial position:

Level 1: quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly.

Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

The InRetail Pharma Group does not maintain any financial instrument with fair value determination under level 3 and there were no transfers between levels during the twelve-month period ended December 31, 2021 and 2020. The InRetail Pharma Group maintains the following financial instruments at fair value:

- Investment at fair value through equity which fair value was determined under level 1 hierarchy.
- Derivative instrument which fair value was determined under level 2 hierarchy.

### 24. Transactions in foreign currency

The financial statements have been stated in Soles using exchange rates prevailing in the market as published by the Superintendence of Banks, Insurance and Pension Funds Administration. As of December 31, 2021 the end of period exchange rates in the market for transactions in US Dollars were S/3.975 per US\$1.00 bid and S/3.998 per US\$ 1.00 ask (S/3.618 and S/3.624 per US\$1.00 for bid and ask as of December 31, 2020).

Transactions in foreign currency are carried out using exchange rates prevailing in the market as published by authorized entities of the country in which the Company and its Subsidiaries operate. As of December 31, 2021 and December 31, 2020, the end of period exchange rate at the market for transactions of the different currency in relation to the Sol are as following:

<u>Exchange rate per Soles</u>	<u>2021</u>	<u>2020</u>
U. S. Dollars (US\$)	0.25	0.276
Bolivian Peso (B\$)	1.741	1.921
Colombian Peso (\$)	-	947.158

## Notes to the interim consolidated financial statements (continued)

As of December 31, 2021 and December 31, 2020, the InRetail Pharma Group held the following foreign currency assets and liabilities:

	As of December 31, 2021		As of December 31, 2020		
	US\$(000)	b\$ (000)	US\$(000)	b\$ (000)	\$(000)
<b>Assets</b>					
Cash and short-term deposits	11,636	21,383	17,158	18,278	621,811
Investments at fair value through equity	43,322	-	14,942	-	-
Trade receivables, net	47,621	31,704	57,308	47,684	9,054,828
Other accounts receivables, net	9,592	3,986	4,086	4,732	-
Accounts receivable from related parties	38	-	-	-	-
<b>Total assets</b>	<b>112,209</b>	<b>57,073</b>	<b>93,494</b>	<b>70,694</b>	<b>9,676,639</b>
<b>Liabilities</b>					
Trade payables	(44,742)	(15,171)	(81,676)	(16,909)	(4,310,221)
Other payables	(6,194)	(7,851)	(8,671)	(8,111)	-
Accounts payable to related parties	(290,597)	-	(13)	-	-
Lease liability	(88,806)	(1,267)	(93,939)	(1,983)	-
Interest - bearing loans and borrowings	(11,007)	-	(417,379)	-	(2,989,968)
<b>Total Liabilities</b>	<b>(441,346)</b>	<b>(24,289)</b>	<b>(601,678)</b>	<b>(27,003)</b>	<b>(7,300,189)</b>
Hedge amount	288,000	-	400,000	-	-
<b>Net (liability) assets position</b>	<b>(41,137)</b>	<b>32,784</b>	<b>(108,184)</b>	<b>43,691</b>	<b>2,376,450</b>

As of December 31, 2021 and December 31, 2020, InRetail Pharma and its Subsidiaries have decided to reduce its exchange rate risk by entering into a hedging operations through a derivative financial instruments written over its intercompany loan with InRetail Consumer and over its "Senior Notes Unsecured", respectively, which is considered an effective hedging instrument.

These instruments have been subscribed for a nominal value of US\$138,000,000, US\$100,000,000 and US\$50,000,000 as of December 31, 2021, the Call Spread protects fluctuations in the exchange rate between S/3.70 and S/4.20 and the Range Only Principal Swap between S/ 3.70 and S/6.00 and will be effective until the maturity of the loans for pay to related parties (as of December 31, 2020, US \$ 400,000,000 protects exchange rate fluctuations between S / 3.26 and S / 3.75 and will be effective until the maturity of the "Senior Notes Unsecured"). See note 8 and 13.

For the twelve-month period ended as of December 31, 2021 and 2020, InRetail Pharma has incurred in the following results for exchange difference:

	2021 S/(000)	2020 S/(000)
Exchange difference generated by hedged assets and liabilities	(114,224)	(122,800)
Compensation of exchange difference for hedging derivative	114,224	122,800
Exchange difference generated by unhedged assets and liabilities	(28,960)	(44,509)
<b>Net loss</b>	<b>(28,960)</b>	<b>(44,509)</b>

### 25. Subsequent event

(a) The Company's Management and its Subsidiaries continue monitoring the evolution of the situation and the guidance of national and international authorities, since events beyond Management's control may arise that require modifying the established business plan. Further spread of COVID-19 and subsequent measures taken to limit the spread of the disease could affect the ability to conduct business in the normal way and therefore affect financial condition and results of operations.

## Notes to the interim consolidated financial statements (continued)

### **26. Additional explanation for English translation**

- (a) The accompanying consolidated financial statements are presented on the basis of the IFRS. Certain accounting practices applied by the InRetail Pharma Group may differ in certain respects from accounting principles generally accepted in other countries. In the event of any discrepancy, the Spanish-language version prevails.